Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crawford joins lobbying firm

This article was originally published in The Tan Sheet

Executive Summary

Former FDA Commissioner Lester Crawford joined the lobbying firm Policy Directions in January as senior counsel. The government relations firm counts the Pharmaceutical Research & Manufacturers of America, the Biotechnology Industry Organization and several major pharmaceutical companies as clients. According to public disclosures, PhRMA paid Policy Directions $120,000 in 2005 to lobby Congress, HHS and FDA on importation, FDA regulation and user fees. Additionally, Merck and Genzyme each paid the firm $80,000 in 2005. According to the firm's website, it was involved in modifying the Controlled Substances Act, it helped garner support for the "Best Pharmaceuticals for Children Act" and "successfully achieved FDA advisory committee support for a product that had originally been voted down." Crawford's abrupt departure from FDA has been under review by the HHS Inspector General (1"The Tan Sheet" Sept. 26, 2005, p. 5)...

You may also be interested in...



Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA

National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner

Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement" Of The Market

United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.

FDA’s Robyn Bent On The Evolution of Patient-Focused Drug Development

The director of the agency’s patient focused drug development program talks to the Pink Sheet about how the program has improved the development and evaluation of new drugs, initiatives underway, and plans to standardize and harmonize the process.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS099066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel